📊 HIMS Key Takeaways
Is HIMS a Good Investment? Thesis Analysis
Hims demonstrates exceptional revenue growth of 59% YoY with an outstanding 73.8% gross margin and a fortress balance sheet (zero debt, $228.6M cash), suggesting a fundamentally sound telehealth business model. However, profitability growth significantly lags revenue expansion (net income +1.8% YoY, EPS -3.8% YoY), indicating operational expense pressures and share dilution that require monitoring for future margin expansion.
Why Buy HIMS? Key Strengths
- Exceptional revenue growth of 59% YoY demonstrates strong market traction and business scalability
- Excellent gross margin of 73.8% reflects strong pricing power and efficient operations in digital healthcare delivery
- Fortress balance sheet with zero long-term debt, $228.6M cash, and healthy liquidity ratios (1.90x current, 1.70x quick) provides significant financial flexibility
- Strong return on equity of 23.7% indicates efficient deployment of shareholder capital despite profitability headwinds
- Positive operating cash flow of $300M supports continued investment in growth and R&D initiatives
HIMS Investment Risks to Consider
- Operating margin of just 4.5% despite 73.8% gross margin signals heavy SG&A burden from customer acquisition and marketing spending
- Net income growth of 1.8% severely trails 59% revenue growth, indicating profitability is not scaling proportionally with topline expansion
- Diluted EPS declining 3.8% YoY despite positive net income growth reveals concerning share dilution and erosion of per-share shareholder value
- Low free cash flow margin of 2.4% despite $300M operating cash flow reflects capital-intensive growth model with substantial CapEx requirements
- Unproven ability to achieve operating leverage; structural margin limitations may emerge as growth moderates
Key Metrics to Watch
- Operating margin expansion trajectory and path to profitability at scale
- Diluted shares outstanding growth rate versus net income CAGR to measure shareholder value creation
- Free cash flow margin trend relative to revenue growth for demonstration of improving capital efficiency
- Operating expense ratio (as % of revenue) progression toward industry benchmarks
- Customer acquisition cost trends and payback periods to validate sustainable unit economics
HIMS Financial Metrics
💡 AI Analyst Insight
The relatively thin 2.4% FCF margin may limit capital allocation flexibility.
HIMS Profitability Ratios
HIMS vs Default Sector
How Hims & Hers Health, Inc. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is HIMS Overvalued or Undervalued?
Based on fundamental analysis, Hims & Hers Health, Inc. has mixed fundamental signals relative to the Default sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
HIMS Balance Sheet & Liquidity
HIMS 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Hims & Hers Health, Inc.'s revenue has grown significantly by 763% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.11 indicates the company is currently unprofitable.
HIMS Growth Metrics (YoY)
HIMS Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $401.6M | $11.1M | $0.06 |
| Q2 2025 | $315.6M | $11.1M | $0.06 |
| Q1 2025 | $278.2M | $11.1M | $0.05 |
| Q3 2024 | $226.7M | -$7.2M | $-0.04 |
| Q2 2024 | $207.9M | -$7.2M | $-0.03 |
| Q1 2024 | $190.8M | -$10.1M | $-0.05 |
| Q3 2023 | $144.8M | -$7.2M | $-0.04 |
| Q2 2023 | $113.6M | -$7.2M | $-0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
HIMS Capital Allocation
HIMS SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Hims & Hers Health, Inc. (CIK: 0001773751)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 10, 2026 | 4 | xslF345X06/wk-form4_1775861797.xml | View → |
| Apr 7, 2026 | 4 | xslF345X06/wk-form4_1775596475.xml | View → |
| Mar 24, 2026 | 4 | xslF345X06/wk-form4_1774390195.xml | View → |
| Mar 18, 2026 | 4 | xslF345X06/wk-form4_1773865063.xml | View → |
| Mar 18, 2026 | 4 | xslF345X06/wk-form4_1773865058.xml | View → |
❓ Frequently Asked Questions about HIMS
What is the AI rating for HIMS?
Hims & Hers Health, Inc. (HIMS) has an AI rating of BUY with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are HIMS's key strengths?
Claude: Exceptional revenue growth of 59% YoY demonstrates strong market traction and business scalability. Excellent gross margin of 73.8% reflects strong pricing power and efficient operations in digital healthcare delivery.
What are the risks of investing in HIMS?
Claude: Operating margin of just 4.5% despite 73.8% gross margin signals heavy SG&A burden from customer acquisition and marketing spending. Net income growth of 1.8% severely trails 59% revenue growth, indicating profitability is not scaling proportionally with topline expansion.
What is HIMS's revenue and growth?
Hims & Hers Health, Inc. reported revenue of $2.3B.
Does HIMS pay dividends?
Hims & Hers Health, Inc. does not currently pay dividends.
Where can I find HIMS SEC filings?
Official SEC filings for Hims & Hers Health, Inc. (CIK: 0001773751) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HIMS's EPS?
Hims & Hers Health, Inc. has a diluted EPS of $0.51.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HIMS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Hims & Hers Health, Inc. has a BUY rating with 72% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is HIMS stock overvalued or undervalued?
Valuation metrics for HIMS: ROE of 23.7% (sector avg: 15%), net margin of 5.5% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy HIMS stock in 2026?
Our dual AI analysis gives Hims & Hers Health, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is HIMS's free cash flow?
Hims & Hers Health, Inc.'s operating cash flow is $300.0M, with capital expenditures of $242.6M. FCF margin is 2.4%.
How does HIMS compare to other Default stocks?
Vs Default sector averages: Net margin 5.5% (avg: 12%), ROE 23.7% (avg: 15%), current ratio 1.90 (avg: 1.8).